Non-alcoholic Steatohepatitis (NASH) treatment market is expected to reach $90.97 billion by 2034, with a CAGR of 28.0%

𝐍𝐨𝐧-𝐚𝐥𝐜𝐨𝐡𝐨𝐥𝐢𝐜 𝐒𝐭𝐞𝐚𝐭𝐨𝐡𝐞𝐩𝐚𝐭𝐢𝐭𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭-𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐒𝐢𝐳𝐞 𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐎𝐮𝐭𝐥𝐨𝐨𝐤, 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰, 𝐚𝐧𝐝 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬. 𝐓𝐡𝐞 𝐧𝐨𝐧-𝐚𝐥𝐜𝐨𝐡𝐨𝐥𝐢𝐜 𝐬𝐭𝐞𝐚𝐭𝐨𝐡𝐞𝐩𝐚𝐭𝐢𝐭𝐢𝐬 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐚𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐰𝐨𝐫𝐭𝐡 𝐔𝐒𝐃 𝟕.𝟕𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟒 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐫𝐞𝐝𝐢𝐜𝐭𝐞𝐝 𝐭𝐨 𝐞𝐱𝐩𝐚𝐧𝐝 𝐭𝐨 𝐔𝐒𝐃 𝟗𝟎.𝟗𝟕 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟒, 𝐰𝐢𝐭𝐡 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟐𝟖.𝟎% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟓 𝐭𝐨 𝟐𝟎𝟑𝟒.

𝐑𝐞𝐩𝐨𝐫𝐭 𝐒𝐜𝐨𝐩𝐞:
This comprehensive study provides an accurate overview of the worldwide non-alcoholic steatohepatitis treatment market. Comprehensive analyses of sales volume, price, revenue, market share, and important companies are included. The market is further divided into segments by drug, disease stage, distribution channel, and region in the study, which offers a comprehensive picture of the state of the market.

𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/non-alcoholic-steatohepatitis-treatment-market/request-for-sample

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐨𝐧:
Non-alcoholic steatohepatitis treatment (NASH) emphasizes controlling liver inflammation and avoiding additional liver harm. It entails lifestyle modifications, such as losing weight, engaging in regular physical activity, and maintaining a nutritious diet to reduce fat buildup in the liver. Medications might be recommended to manage associated conditions such as diabetes or elevated cholesterol. In critical situations, liver transplantation may be an option. Timely intervention aids in reducing disease progression and enhancing liver performance.

𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐓𝐫𝐞𝐧𝐝𝐬:
● The growing older population globally leads to a higher occurrence of NASH-related liver disease, with elderly individuals more susceptible to conditions like diabetes and hypertension associated with NASH. The surging aging population is expected to drive the market forward during the forecast period.

● Insulin resistance, prevalent in diabetes, results in fat buildup in the liver, which initiates liver inflammation and fibrosis linked to NASH. The increasing prevalence of type 2 diabetes is majorly contributing to the market development.

𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬:
Because there are so many companies in the market, it is expected to be both competitive and fragmented. Here are the top companies in the non-alcoholic steatohepatitis treatment market:

• Intercept Pharmaceuticals, Inc.
• Galmed Pharmaceuticals Ltd
• Inventiva
• AbbVie Inc.
• Galectin Therapeutics Inc.
• Madrigal Pharmaceuticals Inc (Madrigal)
• NGM Biopharmaceuticals, Inc.
• Novo Nordisk A/S
• The Bristol-Myers Squibb Company
• Gilead Sciences, Inc.

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
https://www.polarismarketresearch.com/buy/4249/0

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤:
𝐁𝐲 𝐃𝐫𝐮𝐠 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧; 𝟐𝟎𝟐𝟎-𝟐𝟎𝟑𝟒)
• Vitamin E and Pioglitazone
• Obeticholic Acid (OCA)
• Lanifibranor
• Semaglutide
• Resmetirom
• Aramchol
• Cenicriviroc
• Other Drugs

𝐁𝐲 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐒𝐭𝐚𝐠𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧; 𝟐𝟎𝟐𝟎-𝟐𝟎𝟑𝟒)
• NASH Stage F0
• NASH Stage F1
• NASH Stage F2
• NASH Stage F3
• NASH Stage F4

𝐁𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧; 𝟐𝟎𝟐𝟎-𝟐𝟎𝟑𝟒)
• Hospital Pharmacies
• Retail and Specialty Pharmacies
• Other Pharmacies

𝐂𝐨𝐮𝐧𝐭𝐫𝐲-𝐖𝐢𝐬𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
According to regional analysis, North America held the largest market share in 2024 because of the significant occurrence of risk factors like obesity, type 2 diabetes, and metabolic syndrome, which play key roles in the increase of NASH cases.

Also, during the projection period, Asia Pacific is anticipated to witness the highest CAGR. The growing recognition of NASH and its associated complications, along with advancements in healthcare infrastructure and broader access to advanced treatment options, is driving the swift expansion of the market in the region.

o North America (U.S., Canada)
o Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
o Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
o Latin America (Brazil, Mexico, Argentina)
o Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:
Cosmetic Surgery Market
https://www.polarismarketresearch.com/industry-analysis/cosmetic-surgery-market

Hemodialysis and Peritoneal Dialysis Market
https://www.polarismarketresearch.com/industry-analysis/hemodialysis-and-peritoneal-dialysis-market

Hospital Supplies Market
https://www.polarismarketresearch.com/industry-analysis/hospital-supplies-market

India Diagnostic Services Market
https://www.polarismarketresearch.com/industry-analysis/indian-diagnostic-services-market

Intravenous Immunoglobulin Market
https://www.polarismarketresearch.com/industry-analysis/global-intravenous-immunoglobulin-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

𝐀𝐛𝐨𝐮𝐭 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 & 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠, 𝐈𝐧𝐜:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.